ASX:ARXBiotechs
A Look At Aroa Biosurgery’s Valuation After Its Profit Turnaround In Full Year 2026 Results
Why Aroa Biosurgery’s latest earnings matter for ASX:ARX holders
Aroa Biosurgery (ASX:ARX) has drawn fresh attention after reporting full year 2026 results, with sales of NZ$103.85 million and a shift from a net loss to a NZ$4.68 million profit.
See our latest analysis for Aroa Biosurgery.
The latest earnings announcement follows a strong short-term performance, with a 7 day share price return of 13.33% and a 30 day share price return of 21.43%, even though the share price is down 6.85% year...